Literature DB >> 22467037

Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants.

Wen-Hua Xu1, Ai-Mei Zhang, Ming-Shan Ren, Xu-Dong Zhang, Fang Wang, Xiu-Cai Xu, Qing Li, Jian Wang, Bang-Sheng Din, Yuan-Bo Wu, Gui-Hai Chen.   

Abstract

OBJECTIVE: Myasthenia gravis (MG) is a CD4(+) T cell-dependent autoimmune disease, and close attention has been paid to the role of CD4(+)CD25(+)Treg cells (Tregs). Previous results regarding Tregs in MG patients have been conflicting. The discrepancy was partly ascribed to selecting different Treg-associated molecules in defining Tregs. Therefore, we considered it necessary to find a reliable index for assessing the immunologic state in MG patients and explore the effect of IS on them.
METHODS: We adopted flow cytometric techniques to measure the numbers and frequencies of Tregs in peripheral blood taken from 57 patients and 91 age-matched healthy donors, and we also analyzed FOXP3 mean fluorescence intensity on Tregs.
RESULTS: The number and frequency of Tregs in peripheral blood of MG patients significantly decreased, together with down-regulation of FOXP3 expression. There was dynamic change of Treg cell level and the inverse relationship with clinical symptom, suggesting that the immunologic disorder in MG patients was related to peripheral Tregs population. Meanwhile, CD4(+)CD25(+)FOXP3(+)Helios(+)T cells might be activated Tregs, rather than nTregs. Moreover, the number and frequency of CD4(+)CD25(+)FOXP3(+)Helios(+)T cells significantly decreased in MG patients, indicating that the reduction of the activated Tregs population might be a critical contributor to the pathogenesis of MG.
CONCLUSIONS: The significant reduction of the peripheral Tregs population in MG patients might be responsible for the immunologic disorders in MG patients. IS such as GC took its effect possible by increasing the population size, and the underlying mechanism should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467037     DOI: 10.1007/s10875-012-9685-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  32 in total

1.  Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.

Authors:  R S Bedlack; D L Simel; H Bosworth; G Samsa; B Tucker-Lipscomb; D B Sanders
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

2.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

3.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

4.  Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.

Authors:  Y Kuniyasu; T Takahashi; M Itoh; J Shimizu; G Toda; S Sakaguchi
Journal:  Int Immunol       Date:  2000-08       Impact factor: 4.823

5.  Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer.

Authors:  Riki Okita; Yoshiyuki Yamaguchi; Masahiro Ohara; Katsuji Hironaka; Makoto Okawaki; Ichiro Nagamine; Takuhiro Ikeda; Akiko Emi; Jun Hihara; Morihito Okada
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

6.  CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood.

Authors:  Sandra Klein; Cosima C Kretz; Peter H Krammer; Annegret Kuhn
Journal:  J Invest Dermatol       Date:  2009-11-26       Impact factor: 8.551

7.  CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.

Authors:  Luciana L Molinero; Jianying Yang; Thomas Gajewski; Clara Abraham; Michael A Farrar; Maria-Luisa Alegre
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

8.  CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

Authors:  Ismé M de Kleer; Lucy R Wedderburn; Leonie S Taams; Alka Patel; Hemlata Varsani; Mark Klein; Wilco de Jager; Gisela Pugayung; Francesca Giannoni; Ger Rijkers; Salvatore Albani; Wietse Kuis; Berent Prakken
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  Helios expression is a marker of T cell activation and proliferation.

Authors:  Tatiana Akimova; Ulf H Beier; Liqing Wang; Matthew H Levine; Wayne W Hancock
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

10.  Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate.

Authors:  Ye Zheng; Steven Josefowicz; Ashutosh Chaudhry; Xiao P Peng; Katherine Forbush; Alexander Y Rudensky
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962

View more
  14 in total

Review 1.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

2.  Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Authors:  Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi
Journal:  Exp Neurol       Date:  2018-11-22       Impact factor: 5.330

Review 3.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

4.  Differential control of Helios(+/-) Treg development by monocyte subsets through disparate inflammatory cytokines.

Authors:  Hui Zhong; Karina Yazdanbakhsh
Journal:  Blood       Date:  2013-01-30       Impact factor: 22.113

5.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

Review 6.  Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.

Authors:  A Uzawa; S Kuwabara; S Suzuki; T Imai; H Murai; Y Ozawa; M Yasuda; Y Nagane; K Utsugisawa
Journal:  Clin Exp Immunol       Date:  2020-12-03       Impact factor: 5.732

Review 7.  CD4(+)CD25(+) regulatory T cells as a therapeutic target in rheumatoid arthritis.

Authors:  Qing Yu; Man Xu; Fang Yu; Yong Jin
Journal:  Cent Eur J Immunol       Date:  2014-04-17       Impact factor: 2.085

8.  Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects.

Authors:  Frédérique Truffault; Dani Nazzal; Julien Verdier; Angeline Gradolatto; Elie Fadel; Régine Roussin; Bruno Eymard; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

9.  Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis.

Authors:  Yi Li; Shumei Yang; Zhibin Li; Huanyu Meng; Wanling Jin; Huan Yang; Weifan Yin
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

10.  Neuroprotective Effect of Hydrogen-Rich Saline in Global Cerebral Ischemia/Reperfusion Rats: Up-Regulated Tregs and Down-Regulated miR-21, miR-210 and NF-κB Expression.

Authors:  Qian Li; Pan Yu; Qiuting Zeng; Bing Luo; Shenquan Cai; Kangli Hui; Gao Yu; Changsong Zhu; Xingdong Chen; Manlin Duan; Xuejun Sun
Journal:  Neurochem Res       Date:  2016-07-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.